These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24769225)

  • 1. MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.
    Ding G; Zhang Z; Chopp M; Li L; Zhang L; Li Q; Wei M; Jiang Q
    Neuroscience; 2014 Jun; 271():1-8. PubMed ID: 24769225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.
    Zhang L; Chopp M; Teng H; Ding G; Jiang Q; Yang XP; Rhaleb NE; Zhang ZG
    Stroke; 2014 Apr; 45(4):1108-14. PubMed ID: 24549864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
    Li C; Zhang L; Wang C; Teng H; Fan B; Chopp M; Zhang ZG
    Stroke; 2019 Sep; 50(9):2547-2554. PubMed ID: 31387512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen activator related to claudin 5 and occludin disassembly.
    Kaur J; Tuor UI; Zhao Z; Barber PA
    J Cereb Blood Flow Metab; 2011 Sep; 31(9):1874-85. PubMed ID: 21610723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
    Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
    Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
    Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
    Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
    Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
    Allahtavakoli M; Amin F; Esmaeeli-Nadimi A; Shamsizadeh A; Kazemi-Arababadi M; Kennedy D
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):335-9. PubMed ID: 25899606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats.
    Fan X; Jiang Y; Yu Z; Liu Q; Guo S; Sun X; van Leyen K; Ning M; Gao X; Lo EH; Wang X
    Transl Stroke Res; 2017 Dec; 8(6):549-559. PubMed ID: 28580536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats.
    Tan Z; Lucke-Wold BP; Logsdon AF; Turner RC; Tan C; Li X; Hongpaison J; Alkon DL; Simpkins JW; Rosen CL; Huber JD
    Eur J Pharmacol; 2015 Oct; 764():404-412. PubMed ID: 26189021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
    Shimada Y; Shimura H; Tanaka R; Yamashiro K; Koike M; Uchiyama Y; Urabe T; Hattori N
    PLoS One; 2018; 13(5):e0198039. PubMed ID: 29795667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
    Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
    J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.
    Su EJ; Cao C; Fredriksson L; Nilsson I; Stefanitsch C; Stevenson TK; Zhao J; Ragsdale M; Sun YY; Yepes M; Kuan CY; Eriksson U; Strickland DK; Lawrence DA; Zhang L
    Acta Neuropathol; 2017 Oct; 134(4):585-604. PubMed ID: 28725968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.
    Zhang Y; Zhang ZG; Chopp M; Meng Y; Zhang L; Mahmood A; Xiong Y
    J Neurosurg; 2017 Mar; 126(3):782-795. PubMed ID: 28245754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
    Tang J; Li YJ; Mu J; Li Q; Yang DY; Xie P
    Neurol Res; 2009 Mar; 31(2):189-94. PubMed ID: 19298760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat.
    Zhang L; Zhang ZG; Liu XS; Hozeska-Solgot A; Chopp M
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2470-5. PubMed ID: 17717296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier permeability and tPA-mediated neurotoxicity.
    Abu Fanne R; Nassar T; Yarovoi S; Rayan A; Lamensdorf I; Karakoveski M; Vadim P; Jammal M; Cines DB; Higazi AA
    Neuropharmacology; 2010 Jun; 58(7):972-80. PubMed ID: 20060006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
    Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
    Lu HT; Zhao JG; Li MH; Li YD
    Brain Res; 2012 Feb; 1438():75-84. PubMed ID: 22227456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
    Roncal C; Martinez de Lizarrondo S; Salicio A; Chevilley A; Rodriguez JA; Rosell A; Couraud PO; Weksler B; Montaner J; Vivien D; Páramo JA; Orbe J
    Cardiovasc Res; 2017 Aug; 113(10):1219-1229. PubMed ID: 28379489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.